Advanced epithelial ovarian cancer (EOC) is associated with dismal outcome and progression-free survival (PFS) shortens with each subsequent relapse. For patients with recurrent and platinum refractory disease, therapeutic options are limited. Oral metronomic therapy (OMT) is associated with symptomatic relief and stable response in a significant proportion of patients. We retrospectively evaluated the outcome of patients with EOC treated with OMT at a tertiary care hospital in north India.
disease (platinum-free interval from the end of primary chemotherapy >6 months) are treated with paclitaxeland carboplatin-based regimen. For those with platinum-free interval (PFI) less than or equal to six months (platinum-resistant disease), options remain limited 2 . Progression-free survival (PFS) shortens with each subsequent relapse. As a result, after three or four relapses, treatment options are only a few. Metronomic chemotherapy using low-dose cyclophosphamide, etoposide (VP-16), hormonal agents and multikinase inhibitors, e.g., pazopanib has been used for these refractory/recurrent subset of patients with good symptom control and stable disease (SD) in some patients 3, 4 . There are limited published data on the use of metronomic therapy in recurrent and platinum refractory advanced EOC. Here, we report outcome of 36 patients who had recurrent/refractory EOC and were treated with metronomic approach at a tertiary care hospital in north India.
Material & Methods
Between January 2011 and December 2017, 36 patients were identified who had received oral metronomic therapy (OMT); all patients were symptomatic and had clinical and radiological evidence of disease. All patients were registered in the gynaecological tumour clinic and were seen jointly by medical oncology and gynaecologic oncologist and surgical oncologist in the clinic at the Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS), New Delhi, India. Patients were included in this study if they met the following criteria: (i) histologically proven EOC (staged according to FIGO staging); (ii) age >18 yr; (iii) previously treated with at least two lines of platinum-based chemotherapy or who were platinum-resistant/refractory; (iv) adequate organ functions, i.e., haemogram, liver and renal functions; and (v) able to swallow and retain oral medication. The study protocol was approved by the Institutional Ethics Committee. Primary objective of this study was PFS, and secondary outcomes included response rate, toxicity and identification of prognostic factors. Thirty six patients met eligibility criteria and were included for this analysis. The baseline characteristics of the patients are shown in Table I . Demographic details including age, Eastern Cooperative Oncology Group (ECOG) performance status, stage, histopathologic subtype, serum cancer antigen (CA)-125, details of prior treatment and response and major organ toxicities were recorded. Twenty five per cent (n=9) patients had comorbidities at diagnosis: diabetes mellitus in Table II .
Response criteria: Response rates and outcomes were ascertained using serological criteria [Gynecological Cancer Intergroup (GCIG) guidelines] post three cycles and six cycles as well as RECIST 1.1 response criteria 5 . CA-125 response was defined as ≥50 per cent decrease from the baseline CA-125 level and confirmed ≥21 days after initial evaluation (baseline was defined as the higher value of 2 pre-treatment CA-125 assessments). If there were clinical signs and symptoms of progression, CA-125 was done and one more value repeated after 28 days to document clinical as well as serological progression. Progressive disease (PD) was defined as a CA-125 increase ≥100 per cent from nadir value; nadir was defined as the lowest CA-125 level until current assessment. SD was defined as changes in CA-125 not qualifying as either PD or response. The current status of patients was obtained from records and updated telephonically. The toxicity was graded using the Common Terminology Criteria for Adverse Event v.4.03 6 .
Serum CA-125 estimation: CA-125 was done by the Abbott ARCHITECT CA125 II assay (Abbott Laboratories, Abbott Park, IL, USA), which is a chemiluminescent microparticle immunoassay (CMIA) 7 . This assay is a two-step immunoassay to determine the presence of OC Dose modification: For grades 3 and 4 neutropenia, oral etoposide was reduced to 10 (day 1-10) from 14 days (day 1-14) (25-30% reduction). Pazopanib was reduced to 200 mg for patients with liver or skin toxicity. Re-escalation was not done. OMT was stopped in case of progressive disease (Table III) . (Figs 1 and 2 ). There was no significant difference in OS as regards to the number of previous lines of chemotherapy received and the type of OMT received (non-pazopanib versus pazopanib containing). There was a trend for better PFS for patients who received two or more previous lines of chemotherapy (P=0.052) and type of OMT (non-pazopanib versus pazopanib containing) (P=0.0513) ( Fig. 3A and B) . 
Results

Patient characteristics
Discussion
EOC is the second most common gynaecological cancer and is a leading cause of death 6, 8 . With current In recent years, there has been growing interest in the use of 'metronomic-low dose, continuous' therapy for these patients who have been exposed to multiple lines of therapy and have refractory/progressive disease. Seminal work done over the past decade has suggested that main mechanisms behind metronomic therapy are its anti-angiogenesis and effect on T regulatory cells 9, 10 . Angiogenesis has been established as a hallmark of tumour development, growth and metastasis; EOC is particularly sensitive to anti-angiogenic therapy 4, 11 . OMT possibly also works through the regulation of tumour microenvironment 12 .
OMT is yet to carve out its niche in the ovarian carcinoma management spectrum. Large studies like the AGO OVAR trial 13 have established the role of oral drugs such as pazopanib in maintenance therapy. However, its role as a therapeutic agent in refractory and recurrent setting has not been evaluated 14 .
Majority of patients in our study had advanced-stage cancers and presented with poor performance status (ECOG PS 2/3) with a low BMI and nutritional status (median serum albumin 3.8 g/dl). About one-fourth (n=9) had comorbidities.
Different OMT regimens were used in our study based on their efficacy in earlier reports; drugs such as cyclophosphamide, etoposide, pazopanib and celecoxib have been studied for their antiangiogenic and metronomic potential [15] [16] [17] [18] . Pazopanib is a multikinase inhibitor. It inhibits angiogenesis signalling pathway via ATP-competitive inhibition of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3 19 . The MITO 11 trial had evaluated weekly paclitaxel and pazopanib versus paclitaxel in relapsed EOC. The median PFS was superior in combination arm; 6.35 (95% CI: 5·36-11.02) versus 3.49 months (95% CI: 2.01-5.66), HR 0.42 (95% CI: 0.25-0·69); P=0.0002 20 . Several phase-I studies have been conducted to identify the optimal dose of pazopanib 19, 21, 22 . Higher dose of pazopanib was associated with high incidence of hypertension AGO OVAR trial leading to dose modification in 33.3 per cent of patients 14 and other toxicities in two doses of pazopanib (200-400 mg/day). Cyclophosphamide has been established as a metronomic agent over the past decade 18 . A few studies have evaluated cyclophosphamide as a single agent in recurrent carcinoma ovary 17, 18 . PACOVAR study which used a combination of pazopanib with cyclophosphamide demonstrated a median PFS and OS of 6.7 and 15.2 months, respectively 23 (Table V) . The successive decline in PFS with succeeding chemotherapy regimens is a well-known phenomenon in carcinoma ovary. Exploring newer endpoints pertaining to oral metronomic regimens may be the way ahead 1 . Outcomes such as 'chemotherapyfree interval' or interval from the last chemotherapy while on OMT provide us a broad overview of prolongation of survival vis-a-vis maintaining quality of life. Artificial prolongation of platinum-free interval (in hope to improve platinum sensitivity) in patients receiving alternate regimens has been studied extensively and no benefit was displayed in a meta-analysis by Pignata et al 29 . This real-world conundrum might be further validated in prospective studies if a subset of patients who responded better to the OMT initially had improved survival. A study NA, not available done in rural Indian setting has tried to address these concerns 30 .
The OMT regimens used in our study were generally well tolerated with low grades 3 and 4 adverse events. The most common adverse effect was oral mucositis. In patients who are in poor general condition and do not consent for intravenous therapy, offering an oral regimen with low toxicity might be prudent. For response evaluation, the GCIG criteria of serological response and progression was used 5 . RECIST criteria were not used in our study. Our study showed no significant difference in survival as per the number of previous lines of chemotherapy received. In all the studies on metronomic therapy, data available are largely heterogeneous. Majority of the data are retrospective in nature. Doses used in various studies are usually arbitrary and based on physician's discretion. Achieving a standard dose for each oral drug might be difficult as there are various permutations and combination of drugs based on the tolerability of the patients.
The limitations of our study were its retrospective nature, small sample size, wide heterogeneity among patient's groups and therefore, confounding the comparison between the groups. This setting is not uncommon in real-world practice, and based on our results, oral therapy can be utilized as an option in platinum refractory/recurrent EOC. Newer endpoints such as chemotherapy-free interval can be extrapolated and explored in prospective studies.
In conclusion, the results of the present study suggested that OMT could be an option in patients with relapse/refractory EOC. In future, randomized trials on metronomic chemotherapy need to be done in a large number of relapsed/refractory EOC patients.
